Comparative Pharmacology
Head-to-head clinical analysis: M V I PEDIATRIC versus MVC PLUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: M V I PEDIATRIC versus MVC PLUS.
M.V.I. PEDIATRIC vs MVC PLUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Multivitamin preparation providing essential vitamins (A, C, D, E, K, B1, B2, B3, B5, B6, B7, B9, B12) as cofactors for enzymatic reactions, antioxidant functions, and maintenance of normal metabolic processes.
MVC PLUS is a fixed-dose combination of maraviroc, a CCR5 co-receptor antagonist, and lamivudine, a nucleoside reverse transcriptase inhibitor. Maraviroc binds to CCR5 on CD4+ T cells blocking HIV-1 entry; lamivudine inhibits HIV reverse transcriptase via competitive inhibition and chain termination.
Intravenous infusion: 5 mL (1 vial) added to appropriate IV fluid, administered over 30 minutes daily.
10 mg orally once daily.
None Documented
None Documented
Variable; vitamin A: 9-25 days (stored in liver), vitamin D: 2-3 weeks (fat-soluble), vitamin C: 10-20 hours (renal function dependent), B-complex: 1-10 hours. Clinical context: accumulation risk in renal impairment.
Terminal elimination half-life: 12-18 hours (mean 14 hours). Clinically, this supports twice-daily dosing with steady-state achieved in ~3 days.
Renal: 60-80% (free vitamins), Biliary/fecal: 10-20% (unabsorbed and metabolites).
Renal: ~70% unchanged; Fecal: ~25%; Biliary: <5%
Category C
Category C
Multivitamin
Multivitamin/Mineral Supplement